267 related articles for article (PubMed ID: 15944869)
1. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
Birkenfeld AL; Schroeder C; Pischon T; Tank J; Luft FC; Sharma AM; Jordan J
Clin Auton Res; 2005 Jun; 15(3):200-6. PubMed ID: 15944869
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical effect of sibutramine on autonomic cardiovascular regulation.
Birkenfeld AL; Schroeder C; Boschmann M; Tank J; Franke G; Luft FC; Biaggioni I; Sharma AM; Jordan J
Circulation; 2002 Nov; 106(19):2459-65. PubMed ID: 12417543
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
4. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
5. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects.
Heusser K; Tank J; Diedrich A; Engeli S; Klaua S; Krüger N; Strauss A; Stoffels G; Luft FC; Jordan J
Clin Pharmacol Ther; 2006 May; 79(5):500-8. PubMed ID: 16678551
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
7. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
[TBL] [Abstract][Full Text] [Related]
8. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
Hazenberg BP
Cardiology; 2000; 94(3):152-8. PubMed ID: 11279320
[TBL] [Abstract][Full Text] [Related]
11. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
13. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
Zannad F; Gille B; Grentzinger A; Bruntz JF; Hammadi M; Boivin JM; Hanotin C; Igau B; Drouin P
Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
[TBL] [Abstract][Full Text] [Related]
14. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
[TBL] [Abstract][Full Text] [Related]
16. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
Jordan J; Scholze J; Matiba B; Wirth A; Hauner H; Sharma AM
Int J Obes (Lond); 2005 May; 29(5):509-16. PubMed ID: 15685250
[TBL] [Abstract][Full Text] [Related]
17. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.
Faria AN; Ribeiro Filho FF; Lerario DD; Kohlmann N; Ferreira SR; Zanella MT
Arq Bras Cardiol; 2002 Feb; 78(2):172-80. PubMed ID: 11887193
[TBL] [Abstract][Full Text] [Related]
18. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
[TBL] [Abstract][Full Text] [Related]
19. Sibutramine and the sympathetic nervous system in obese humans.
Haynes WG; Egri Z
Clin Auton Res; 2005 Jun; 15(3):189-92. PubMed ID: 15944867
[No Abstract] [Full Text] [Related]
20. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP;
Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
